Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dose-Dense Docetaxel in Newly Diagnosed Breast Cancer
NCT00080626Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Correlation between change in apoptosis and proliferation with response after definitive surgery. Started Aug 2003; status: terminated.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00080626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080626.